296 related articles for article (PubMed ID: 25379018)
1. The presence of telomere fusion in sporadic colon cancer independently of disease stage, TP53/KRAS mutation status, mean telomere length, and telomerase activity.
Tanaka H; Beam MJ; Caruana K
Neoplasia; 2014 Oct; 16(10):814-23. PubMed ID: 25379018
[TBL] [Abstract][Full Text] [Related]
2. Telomerase and telomere length in the development and progression of premalignant lesions to colorectal cancer.
Engelhardt M; Drullinsky P; Guillem J; Moore MA
Clin Cancer Res; 1997 Nov; 3(11):1931-41. PubMed ID: 9815582
[TBL] [Abstract][Full Text] [Related]
3. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
[TBL] [Abstract][Full Text] [Related]
4. KRAS mutations in traditional serrated adenomas from Korea herald an aggressive phenotype.
Kim KM; Lee EJ; Kim YH; Chang DK; Odze RD
Am J Surg Pathol; 2010 May; 34(5):667-75. PubMed ID: 20305537
[TBL] [Abstract][Full Text] [Related]
5. Genetic analysis in APC, KRAS, and TP53 in patients with stomach and colon cancer.
Palacio-Rúa KA; Isaza-Jiménez LF; Ahumada-Rodríguez E; Muñetón-Peña CM
Rev Gastroenterol Mex; 2014; 79(2):79-89. PubMed ID: 24861525
[TBL] [Abstract][Full Text] [Related]
6. The prognostic role of microsatellite instability, codon-specific KRAS, and BRAF mutations in colon cancer.
Lin CC; Lin JK; Lin TC; Chen WS; Yang SH; Wang HS; Lan YT; Jiang JK; Yang MH; Chang SC
J Surg Oncol; 2014 Sep; 110(4):451-7. PubMed ID: 24964758
[TBL] [Abstract][Full Text] [Related]
7. Multiple intratumoral KRAS mutations can clonally segregate to different lymph node metastases in colon cancer.
Jahn SW; Winter G; Stacher E; Halbwedl I; Gattenlöhner S; Stockinger R; Spreitzer S; Waldispuehl-Geigl J; Geigl JB; Offner F; Hoefler G
Histopathology; 2011 Aug; 59(2):342-5. PubMed ID: 21884216
[No Abstract] [Full Text] [Related]
8. Integrative approach for prioritizing cancer genes in sporadic colon cancer.
Reid JF; Gariboldi M; Sokolova V; Capobianco P; Lampis A; Perrone F; Signoroni S; Costa A; Leo E; Pilotti S; Pierotti MA
Genes Chromosomes Cancer; 2009 Nov; 48(11):953-62. PubMed ID: 19672874
[TBL] [Abstract][Full Text] [Related]
9. Influence of anatomical subsite on the incidence of microsatellite instability, and KRAS and BRAF mutation rates in patients with colon carcinoma.
Benedix F; Meyer F; Kube R; Kropf S; Kuester D; Lippert H; Roessner A; Krüger S
Pathol Res Pract; 2012 Oct; 208(10):592-7. PubMed ID: 22898351
[TBL] [Abstract][Full Text] [Related]
10. Relative telomere lengths in tumor and normal mucosa are related to disease progression and chromosome instability profiles in colorectal cancer.
Suraweera N; Mouradov D; Li S; Jorissen RN; Hampson D; Ghosh A; Sengupta N; Thaha M; Ahmed S; Kirwan M; Aleva F; Propper D; Feakins RM; Vulliamy T; Elwood NJ; Tian P; Ward RL; Hawkins NJ; Xu ZZ; Molloy PL; Jones IT; Croxford M; Gibbs P; Silver A; Sieber OM
Oncotarget; 2016 Jun; 7(24):36474-36488. PubMed ID: 27167335
[TBL] [Abstract][Full Text] [Related]
11. Integrative marker analysis allows risk assessment for metastasis in stage II colon cancer.
Nitsche U; Rosenberg R; Balmert A; Schuster T; Slotta-Huspenina J; Herrmann P; Bader FG; Friess H; Schlag PM; Stein U; Janssen KP
Ann Surg; 2012 Nov; 256(5):763-71; discussion 771. PubMed ID: 23095620
[TBL] [Abstract][Full Text] [Related]
12. [Mutations of KRAS and BRAF in Chinese patients with colorectal carcinoma: analyses of 966 cases].
Gao J; Sun ZW; Li YY; Shen L
Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):579-83. PubMed ID: 23157823
[TBL] [Abstract][Full Text] [Related]
13. Microsatellite instability and mutations in BRAF and KRAS are significant predictors of disseminated disease in colon cancer.
Birgisson H; Edlund K; Wallin U; Påhlman L; Kultima HG; Mayrhofer M; Micke P; Isaksson A; Botling J; Glimelius B; Sundström M
BMC Cancer; 2015 Mar; 15():125. PubMed ID: 25884297
[TBL] [Abstract][Full Text] [Related]
14. Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages.
Li W; Qiu T; Zhi W; Shi S; Zou S; Ling Y; Shan L; Ying J; Lu N
BMC Cancer; 2015 May; 15():340. PubMed ID: 25929517
[TBL] [Abstract][Full Text] [Related]
15. A mutation spectrum that includes GNAS, KRAS and TP53 may be shared by mucinous neoplasms of the appendix.
Hara K; Saito T; Hayashi T; Yimit A; Takahashi M; Mitani K; Takahashi M; Yao T
Pathol Res Pract; 2015 Sep; 211(9):657-64. PubMed ID: 26160192
[TBL] [Abstract][Full Text] [Related]
16. Impact of KRAS and TP53 mutations on survival in patients with left- and right-sided Dukes' C colon cancer.
Bleeker WA; Hayes VM; Karrenbeld A; Hofstra RM; Hermans J; Buys CC; Plukker JT
Am J Gastroenterol; 2000 Oct; 95(10):2953-7. PubMed ID: 11051374
[TBL] [Abstract][Full Text] [Related]
17. Oxidative DNA damage in Barrett mucosa: correlation with telomeric dysfunction and p53 mutation.
Cardin R; Piciocchi M; Tieppo C; Maddalo G; Zaninotto G; Mescoli C; Rugge M; Farinati F
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S583-9. PubMed ID: 23744553
[TBL] [Abstract][Full Text] [Related]
18. [Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas].
Zhang X; Wang Y; Gao N; Wang J
Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):77-82. PubMed ID: 24742565
[TBL] [Abstract][Full Text] [Related]
19. Reduced telomere length in colorectal carcinomas.
Feng TB; Cai LM; Qian KQ; Qi CJ
Asian Pac J Cancer Prev; 2012; 13(2):443-6. PubMed ID: 22524803
[TBL] [Abstract][Full Text] [Related]
20. Functional TP53 mutations have no impact on response to cytotoxic agents in metastatic colon cancer.
Netter J; Lehmann-Che J; Lambert J; Tallet A; Lourenco N; Soliman H; Bertheau P; Pariente B; Chirica M; Pocard M; Allez M; De The H; Gornet JM
Bull Cancer; 2015 Feb; 102(2):117-25. PubMed ID: 25609485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]